Clinical trials: Pulmonary Artery Hypertension
Hypertension, Pulmonary
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to…
- Trial name
- PATENT-CHILD (NCT02562235)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 16 sites in Colombia, Germany and 7 more
- Volunteers
- 24 people
- Sponsor
- Bayer
Pulmonary Hypertension
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- FREEDOM-C2 (NCT00887978)
- Testing
- UT-15C SR
- Where
- 62 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Cognitive Alterations in Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension (PAH) is a rare chronic disease marked by a pathological and sustained increase in pulmonary artery pressure as a result of structural and functional changes within the pulmonary vasculature.
- Trial name
- COG-PAH (NCT07391228)
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Alessandra Gorini
Pulmonary Arterial Hypertension
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
- Trial name
- NCT01484431
- Testing
- Tadalafil- Tablet or Oral suspension
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
High Altitude, Six-minute Walk Test
Assessment of Six-minute Walking Distance 6MWD Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of descent from high altitude (Quito Ecuador: 2850m) to sea level on six-minute walking distance and scores in healthy individuals, who live permanently >2600m.
- Conditions
- High Altitude, Six-minute Walk Test, High Altitude Effects, Healthy
- Trial name
- NCT07801872
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension
Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.
- Trial name
- NCT01251835
- Testing
- Sitaxsentan alone, Sitaxsentan, Rifampin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension, Children
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years.
- Trial name
- NCT00159913
- Testing
- Sildenafil citrate
- Where
- 41 sites in United States, Brazil and 15 more
- Volunteers
- 235 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate patterns of metabolic activity in the heart of patients with pulmonary arterial hypertension(PAH).
- Trial name
- RVMET (NCT01572077)
- Testing
- FTHA, FDG PET imaging.
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Pulmonary Hypertension
Genetic Research of Bone Morphogenetic Protein Receptor-II Gene in Taiwanese Patient With Primary Pulmonary Hypertension
Primary pulmonary hypertension (PPH) is a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason.
- Trial name
- NCT00173537
- Testing
- for BMPR II study, BMPRII
- Where
- Taiwan
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Pulmonary Arterial Hypertension
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH.
- Trial name
- ViTAL-PH (NCT06846554)
- Testing
- APL-9796
- Where
- 6 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Apollo Therapeutics Ltd
Portopulmonary Hypertension, Pulmonary Arterial Hypertension
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
This was a multicenter, prospective, observational, open-label study. Patients meeting inclusion/exclusion criteria received treatment with treprostinil as recommended by their treating physicians and were followed according to…
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Trial name
- NCT01028651
- Testing
- Treprostinil
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Rutgers University Study of the Genetics of Pulmonary Hypertension
The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligible, and a diagnosis of PH is NOT required.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- RUGCC-PH (NCT07217522)
- Testing
- Saliva sample, Health surveys
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Hypertension, Pulmonary
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial…
- Trial name
- AMBITION (NCT01178073)
- Testing
- ambrisentan, tadalafil
- Where
- 143 sites in United States, Australia and 12 more
- Volunteers
- 610 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers
In this prospective study, the investigators will implement a systematic screening program and 3-year follow-up in a cohort of asymptomatic BMPR2 mutation carriers.
- Trial name
- DELPHI-2 (NCT01600898)
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypertension, Pulmonary
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
- Trial name
- SALTO (NCT04175600)
- Testing
- Selexipag, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor
- Where
- 116 sites in United States, Australia and 30 more
- Volunteers
- 138 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension
To assess the correlation between pulmonary IV-OCT and pulmonary IV-US measurements and standard PAH clinical measures of disease progression and the relative sensitivity of the techniques to change.
- Trial name
- NCT03105934
- Testing
- Patients with Pulmonary Arterial Hypertension
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).
- Trial name
- PATENT-1 (NCT00810693)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 122 sites in United States, Argentina and 28 more
- Volunteers
- 445 people
- Sponsor
- Bayer
Hypertension, Pulmonary
First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the strategy of initiating double oral combination therapy with bosentan and sildenafil at the time of diagnosis of pulmonary arterial hypertension (PAH) in a preliminary way.
- Trial name
- NCT01247116
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Calgary
Pulmonary Arterial Hypertension
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
An Investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, clinical study design.
- Trial name
- TAPE (NCT04972656)
- Testing
- Ambrisentan
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Pulmonary Hypertension Biorepository and Registry
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary
- Trial name
- PHBR (NCT04808596)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Kansas Medical Center